Scientific Advisory Board (SAB): Elasmogen has attracted the advice and support of a world class scientific Board that includes pharma professionals, antibody technology pioneers, award winning biotechnology entrepreneurs and clinicians regarded as the top in their respective fields.
Mr Jones brings 25 years of success leading new medical products from concept through to market adoption in VC and Fortune 500 companies. Currently Chairman of Mologic, and NED for Deltex Medical, MediSieve and Health Enterprise East, Mr Jones is a US national who came to the UK in 2008 to become CEO of GlySure. He has raised over $40 M in funding from Venture, Corporate and Angel investors. At GlySure he led the development and CE approval of the world’s first continuous intravascular glucose sensor. From 2005-2008 he was CEO of Tensys Medical developing and commercialising the first continuous NIBP monitor resulting in the sale of the company in 2008. In his current role Mr Jones provides both strategic direction and hands-on support for critical areas including: market assessment, commercialisation, partnerships and IP strategy. Mr Jones is a graduate of Yale University with a B.S. in Molecular Biophysics and Biochemistry.
Dr Caroline Barelle
With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background. She has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She is a member of the Enterprise, Skills and Strategy Board (ESSB), the Opportunity North East Board (ONE), the RS Entrepreneur in Residence for Queen’s University Belfast and sits on the Royal Society Science, Industry and Translation Committee.
She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry and has an MBA from Robert Gordon University.
Professor Andy Porter FRSB, FRSE
Chief Technical Officer
Andy was one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy. He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen. Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business. Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19. Andy is a graduate of St Andrews University.
Dr Savvas Neophytou is partner at Deepbridge Capital LLP where he heads up the firm’s Life Sciences business. Savvas also co-founded Acorn Partners, a joint venture between Deepbridge Capital, Alder Hey Hospital and software engineers WeAreNova. He is a founding shareholder of a number of technology companies including Torafugu Tech and Cerneretec. Torafugu is engaged in the emerging field of data driven enablers to improve health outcomes and Cerneretec is engaged in the development of point of care diagnostics for the acute care hospital setting. He has also been CEO of Now Healthcare Group, an online doctor platform where he was part of the original team that set up Europe’s largest telehealth platform. Prior to that Savvas had a long career in the City, working for 15 years as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. Sav holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.
Keith has been an Investor at BGF since 2015 leading investments across the North of Scotland. BGF are a £2.5bn fund supporting earlier stage and established private businesses, and smaller listed companies in the UK. Prior to joining BGF, Keith was an Investment Manager at Souter Investments, working primarily on investments in the transport sector. Keith originally trained and qualified as a solicitor at Shepherd and Wedderburn and has an LLB honours degree and Diploma in Legal Practice from the University of Aberdeen.
Non Executive Director
Jane has over 30 years’ experience in the life science industry across biotech, pharma and agrochemicals. She is currently Chair of Spirea and PharmEnable and an NED at Elasmogen, Macomics and Nanosyrinx. Her past roles include Chief Business Officer at F-star, Vice President of Business Development at Cellzome, and Director of Business Development at MedImmune (formerly Cambridge Antibody Technologies). The first part of her career was spent in the agrochemical industry in research and project management. She is the Chair of the Sir Richard Stapley Educational Trust.
Jane holds an MA and PhD in Natural Sciences from Cambridge University, as well as an MBA from the Cambridge Judge Business School.